Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Causes and consequences of aberrant mRNA translation in cancer

Descrizione del progetto

Sintesi proteica alterata e progressione del cancro

Quando le cellule T si attivano in risposta al cancro, rilasciano l’interferone gamma che innesca la conversione del triptofano in chinurenina. Sebbene la chinurenina contribuisca a sopprimere l’attività delle cellule T contro il tumore, la sua produzione riduce anche la disponibilità di triptofano per le cellule tumorali stesse. Questo spesso causa errori nella sintesi proteica e porta alla produzione di proteine anomale, che possono favorire la crescita del tumore e le metastasi. Il progetto pepTalks, finanziato dal CER, si propone di studiare le implicazioni della traduzione aberrante dell’mRNA nel cancro e di sviluppare strategie terapeutiche innovative mirate a questi processi.

Obiettivo

Shortages in amino acids are weapons in the warfare between tumor cells and tumor-infiltrating lymphocytes. Tumor cells enhance or inhibit the production of key amino acid metabolites to stimulate oncogenesis and suppress anti-tumor activity. A key player in this battle is tryptophan. Activated T cells secrete interferon-, which upregulates IDO1 enzyme to catabolize tryptophan to kynurenine in target tumor cells. While kynurenine suppresses T-cell function, its production limits tryptophan availability in tumor cells. Importantly, as tumor cells almost invariably deregulate mRNA translation to promote proliferation and metastasis, the consequences of tryptophan shortage are major. It provokes aberrant mRNA translation at tryptophan codons, resulting in ribosomal frameshifting and tryptophan to phenylalanine (W>F) codon reassignments (substitutants). This aberrant mRNA translation alters protein function and enriches the landscape of neoepitopes at the surface of tumor cells. Based on these observations, I hypothesize here that the detection of aberrant proteins in cancer specimens can reveal additional key processes of cancer progression beyond tryptophan that can be utilized for cancer therapy.

To explore this exciting new idea, I designed three work packages (WPs):
WP1 will expand the landscape of aberrant mRNA translation in cancer and link them to cancerous events. Preliminary results pinpoint arginine, histidine, and leucine.
WP2 will generate reporter assays, set up functional genetic screens, and identify, validate, and explore key regulators of aberrant mRNA translation.
WP3 will study the functional consequences of aberrant mRNA translation, and introduce novel therapeutic concepts.
Altogether, this proposal will employ our recent discoveries of aberrant mRNA translation during periods of amino acid shortages to explore novel interplays between cancers and their suppressive microenvironment, and utilize this new knowledge for cancer therapy.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2023-ADG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Contributo netto dell'UE
€ 2 500 000,00
Costo totale
€ 2 500 000,00

Beneficiari (1)